YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$12.87 USD
-0.74 (-5.44%)
Updated May 9, 2024 04:00 PM ET
After-Market: $12.84 -0.03 (-0.23%) 5:10 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 61 - 80 ( 147 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DANYELZA Receives Priority Review in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Weakness Provides Attractive Entry Point; 2Q21 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DANYELZA Submitted for Approval in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Application Resubmission Initiation in 4Q21; Lowering PT to $68
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Light at the End of the Tunnel for Omburtamabs BLA?
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DANYELZA and Omburtamab Incremental Data Presented at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Myriad Upcoming Catalysts; 1Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Submitted to European Regulator for Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab FDA Update; Resubmission Timeline Maintained; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Continue to View DANYELZA Favorably; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Resubmission Progress; 2020 Financial Results; Raising PT to $70
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FY 2020 Financials; Danyelza Makes it to Market
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Priority Review Voucher From DANYELZA FDA Approval Sold for $105M; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Two Regional Agreements Inked For DANYELZA and Omburtamab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R